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Objectives. To evaluate, in a group of nondiabetic
essential hypertensive patients with normal renal
function, the relationship between albumin
excretion rate (AER) and carotid-femoral pulse
wave velocity (PWV), as an index of aortic stiffness.
Design. Cross-sectional study.
Setting. Outpatient hypertension clinic.
Subjects. Seventy patients with mild-to-moderate
essential hypertension, aged 42  8 years, never
pharmacologically treated. All subjects underwent
routine laboratory tests, 24-h ambulatory blood
pressure (BP) monitoring, measurement of carotid-
femoral PWV, by means of a computerized method,
and AER.
Results. Microalbuminuric patients (AER 
20 lg min1; n ¼ 19), when compared with
normoalbuminuric subjects, showed more elevated
24-h BP (136/88  10/10 vs. 128/83  7/
6 mmHg; P < 0.001 and P ¼ 0.013, for systolic
and diastolic BP respectively) and higher values of
carotid-femoral PWV (10.4  2 m s1 vs.
9.2  1.3; P ¼ 0.006). This latter difference
remained statistically significant, even after
correction by ancova for 24-h systolic and diastolic
BP, and body mass index (BMI, P ¼ 0.016).
Univariate regression analysis disclosed a tight
correlation between AER and carotid-femoral PWV
(r ¼ 0.42; P ¼ 0.0003). This association was
confirmed in a multiple regression model (b ¼ 0.35;
P ¼ 0.009) in which, as independent variables,
besides PWV, 24-h BP, age, serum glucose values,
smoking status, gender and BMI, were added.
Conclusions. Our results seem to confirm that
microalbuminuria may represent the early renal
manifestation of a widespread vascular dysfunction,
and therefore it is an integrated marker of
cardiovascular risk.
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Introduction
It has been clearly demonstrated that microalbu-
minuria is an early sign of increased risk for
developing overt nephropathy and cardiovascular
disease in type 1 and type 2 diabetes [1]. Recently, a
large body of evidence has been published suggest-
ing that the value of microalbuminuria as predictor
of organ damage [2–10] and of cardiovascular
events and total mortality [11–18] may be extended
to nondiabetic subjects and to patients with essential
hypertension. In some of these studies [17–18] the
relationship of albumin excretion rate (AER) with
cardiovascular complications was already apparent
at levels of albuminuria currently considered to be
normal (i.e. in timed urine collections
<20 lg min1).
Large artery stiffening plays an important role in
cardiovascular diseases, and there is an increasing
interest on noninvasive methods of measurement of
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arterial compliance. Most of them are complex or
need sophisticated technical equipment, which lim-
its their application in clinical practice. Amongst the
simplest method of evaluating arteries, pulse wave
velocity (PWV) measurement is widely used as an
index of large artery compliance [19]. The basic
principle of PWV assessment is that the pulse wave
runs along with the arterial tree at a speed, which
depends upon the elasticity of the wall itself:
the stiffer (i.e. less elastic) the wall the higher the
velocity of propagation. PWV measured along the
aortic and aortoiliac pathway is the most clinically
relevant as the aorta and its first branches are
responsible for most of the pathophysiological effects
of arterial stiffness [19]. This surrogate index of
aortic compliance has been shown to predict
cardiovascular mortality in end-stage renal disease
[20], in patients with essential hypertension [21]
and in subjects with diabetes and glucose intoler-
ance [22].
It has long been recognized that PWV is increased
in kidney diseases, and the association of impaired
renal function with decreased arterial elasticity is
firmly established [19, 23].
In contrast, little is known about the relationships
between microalbuminuria and large-artery stiffness
[24–29].
Accordingly, the present study was undertaken to
explore the relationships between AER and aortic
PWV in a group of young and middle aged nondi-
abetic essential hypertensives with normal renal
function.
Methods
The study population consisted of 70 essential
hypertensives, aged between 23 and 61 years,
referred to our outpatient hypertension centre,
between October 2002 and July 2003. Patients
with hypertension were included in the study, if they
were newly diagnosed (within the previous 2 years),
had never been previously pharmacologically trea-
ted, and had mild-to-moderate essential hyperten-
sion, as defined according to the 2003 European
Society of Hypertension-European Society of Cardi-
ology guidelines [30]. Exclusion criteria were: sec-
ondary or malignant hypertension, heart failure,
positive history or clinical signs of ischaemic heart
disease, cerebrovascular disease, renal insufficiency
(serum creatinine: >1.5 mg dL1 in men and
>1.4 mg dL1 in women), overt proteinuria
(AER > 200 lg min1), major noncardiovascular
diseases, dyslipidaemia requiring pharmacological
treatment, and known diabetes or fasting glycaemia
126 mg dL1. Only patients with reliable urine
collections were recruited.
Secondary hypertension was ruled out by clinical
examination, and determination of serum creati-
nine, serum and urinary electrolytes, plasma renin
activity, plasma aldosterone, plasma catecholamines
and renal echography.
The local ethics committee approved the study
protocol. Written informed consent was obtained
from each patient.
In all subjects careful clinical history and physical
examination were performed. Body weight and
height were measured and body mass index (BMI)
was calculated as weight to height squared.
Clinic blood pressure (BP) and heart rate were
recorded by an automatic validated oscillometric
device (Omron HEM 705 CP, OMRON Healthcare,
Hamburg, Germany) [31], after the subject had been
supine for 5 min. Three consecutive measurements
were taken at 2-min intervals and averaged.
Moreover, fasting blood samples were taken to
perform routine blood chemistry, and a 24-h urine
sample was collected to evaluate the levels of
microalbuminuria and creatinine. Twenty-four hour
urine collection was repeated within 1 week to
assay again microalbuminuria. Both urine collec-
tions were carried out on two nonworking days. The
patients were advised to avoid excessive physical
efforts on the day before and during the 24-h urine
collections.
Microalbuminuria was analysed by a solid-phase
enzyme immunoassay (Microalbumin-ELISA, DRG
Diagnostics, Marburg, Germany). The sensitivity of
this method is 0.5 lg mL1, and the intra-assay and
interassay coefficient of variation were 3.6% and
2.9%, respectively.
The average of two AER determinations was
considered as the level of albuminuria in each
subject.
The currently considered threshold for the defini-
tion of microalbuminuria [1] was used to separate
microalbuminuric (AER  20 lg min1) from
normoalbuminuric subjects (AER < 20 lg min1).
In three subjects with urinary tract infections
microalbuminuria was determined only after appro-
priate antibacterial treatment.
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Determination of routine biochemical parameters
was performed with standard techniques by using
an autoanalyzer (Boehringer Mannheim for Hitachi
system 911, Germany). Low-density lipoprotein
(LDL) cholesterol was calculated by the Friedwald
formula.
Aortic compliance was assessed by automatic
carotid-femoral PWV measurement using the
Complior (Colson, Garges les Gonesse, France), a
computerized device that allows on-line pulse wave
recording and automatic calculation of PWV, as
previously described and validated by Asmar et al.
[32]. Aortic PWV was computed from the time delay
between the recorded proximal (carotid) and distal
(femoral) feet of the wave, and the superficially
measured distance separating the respective pres-
sure-sensitive transducers. It was determined as the
average of at least 10 cardiac cycles. All measure-
ments were carried out by the same observer (G.M.),
unaware of the patient’s AER data.
We performed a reproducibility study amongst
eight participants, who underwent a second PWV
evaluation within 1 week after the first examination.
The mean (SD) difference between the two measure-
ments was 0.32 (0.88) m s1. The mean intraob-
server variability [(first measurement  second
measurement/first measurement)  %] was 3.37%.
Furthermore, all patients underwent 24-h ambu-
latory blood pressure monitoring (ABPM), by means
of a portable noninvasive SpaceLabs 90207 recorder
(Redmond, WA, USA). The device was applied in the
morning to the nondominant arm and removed the
next day at our hypertension unit.
Only records with more than 80% of valid data
were accepted.
Statistics
The planned study sample size (70 participants) was
calculated on the basis of previous investigations
exploring the same issue [26, 27], assuming to find
a coefficient of correlation between AER and PWV of
at least 0.40. On this basis, it was estimated that the
study would have 93% power to detect the expected
result (with a ¼ 0.05).
Continuous variables were given as mean  SD,
except for AER, which because of its skewed
distribution, was expressed as the median and
interquartile range. It was therefore log-transformed
before starting the statistical tests.
Differences between groups were evaluated using
the Student’s t-test for unpaired data. Adjustment
for some confounding variables was made by
ancova. For the categorical variables, comparisons
were carried out using the chi-square test, with
Yates’ correction.
Simple and stepwise multiple regression analyses
were used to test the relationships between micro-
albuminuria (log-transformed), PWV and other
variables.
The null hypothesis was rejected at a two-tailed
P  0.05.
The statistical analyses were performed using the
SYSTAT DATA software package, version 5.2
(Systat, Evanston, IL, USA).
Results
In the whole study population the median value
(and interquartile range) of AER was 15.3 (6.6–
27.2) lg min1 and the PWV was 9.6  1.7 m s1.
Table 1 gives some clinical and demographic char-
acteristics of the 70 patients included in the statis-
tical analysis and of the microalbuminuric
(AER  20 lg min1) and normoalbuminuric sub-
jects (AER < 20 lg min1). In the group of patients
with higher AER a tendency towards greater values
of BMI was observed. Moreover, clinic and 24-h
systolic BP, as well as clinic mean BP and 24-h
mean and diastolic BP, were significantly higher in
the subset of microalbuminuric hypertensives. These
latter showed also faster PWV (10.4  2 m s1 vs.
9.2  1.3; P ¼ 0.006) (Fig. 1) when compared
with normoalbuminuric subjects, even after adjust-
ment by ancova for 24-h systolic and diastolic BP,
and BMI (P ¼ 0.016).
Similar results were obtained when, instead of the
traditional cut-off of 20 lg min1, we used a lower
limit that is the median value of AER
(15.3 lg min1), to separate the study population
into two subgroups. Indeed, PWV was higher in the
subset of hypertensives with AER above the median
(n ¼ 35) when compared with those with AER
below the median (10.2  1.7 vs. 8.9  1.3 m s1;
P ¼ 0.002).
In our study population females were older than
males (45.6  8.5 vs. 40.3  8.1 years; P ¼ 0.01).
No difference was found between males and females
regarding PWV (9.7  1.6 vs. 9.5  1.7 m s1).
However, adjustment for age disclosed a trend
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towards faster PWV in males compared with females
(9.9  1.7 vs. 9.1  1.6 m s1; P ¼ 0.052). More-
over, AER was slightly higher in males than it was
in females [15.4 (7.8–32-9) vs. 9.2 (3.3–15.3);
P ¼ 0.03]. In current smokers PWV tended to be
higher than it was in those who had never smoked
(10.1  1.8 vs. 9.2  1.7; P ¼ 0.06). On the con-
trary, no difference was found between these two
subgroups with respect to AER [13.6 (7.4–18.4) vs.
14.1 (6.4–19.2)].
Simple regression analysis disclosed significant
correlations between AER, PWV and some clinical
and demographic variables, which are summarized
in Table 2. Furthermore, a tight correlation
between AER (log-transformed) and aortic PWV
was found (r ¼ 0.42; P ¼ 0.0003) (Fig. 2). This
association was confirmed (b ¼ 0.35; P ¼ 0.009)
in a multiple regression model (R2 ¼ 0.44) in
which, as independent variables besides PWV, all
the parameters related to AER or PWV in univa-
riate analyses (24-h systolic and diastolic BP, age,
serum glucose values, smoking status, gender and
BMI) were added. The inclusion into this model of
clinic BP values, instead of 24-h ambulatory BP,
did not significantly modify the results (b ¼ 0.37;
P ¼ 0.007). The same was true when 24-h systolic
and diastolic BP were replaced by 24-h pulse and
Table 1 Some demographic and clinical characteristics of the seventy subjects included in the analysis and of the microalbuminuric
(AER  20 lg min1) and normoalbuminuric subjects (AER < 20 lg min1)
Whole
population
(n ¼ 70)
Normoalbuminuric
subjects (AER < 20 lg min1)
(n ¼ 51)
Microalbuminuric
subjects (AER  20 lg min1)
(n ¼ 19) P-value
Age (years) 42.2  8.1 42.4  8.3 41.5  7.7 0.682
Sex distribution (M/F) [n (%)] 44/26 (63/37) 31/20 (61/39) 13/6 (68/32) 0.757
Smokers [n (%)] 0.14*
Current 19 (27) 14 (27) 5 (26)
Former 15 (21) 8 (16) 7 (37)
Never 36 (52) 29 (57) 7 (37)
Body mass index (kg m2) 26.9  5.6 26.1  5.7 28.8  4.9 0.072
Glycaemia (mg dL1) 90.6  10.2 89.5  9.8 92.8  11 0.23
Total cholesterol (mg dL1) 204.8  38.2 208.1  40.4 197.2  32.2 0.295
Triglycerides (mg dL1) 102.1  44.1 102  41.3 102.4  51.3 0.973
HDL cholesterol (mg dL1) 49.4  11.4 50.1  12.7 48  7.7 0.502
LDL cholesterol (mg dL1) 135  32.4 137.7  35.4 128.7  23.7 0.31
Serum creatinine (mg dL1) 0.81  0.15 0.81  0.16 0.82  0.13 0.808
Creatinine clearance (mL min1) 111.4  28.3 108.1  30.6 119  20.7 0.157
Clinic systolic BP (mmHg) 147.4  16 143.1  16.5 151.9  14.4 0.044
Clinic diastolic BP (mmHg) 95.4  9.3 93.4  9.6 97.7  8.8 0.093
Clinic pulse pressure (mmHg) 52  11.5 49.7  13.9 54.2  9.1 0.195
Clinic mean BP (mmHg) 112.7  10.3 110  10.3 115.7  10.3 0.043
24-h systolic BP (mmHg) 131.5  8.7 128.2  7.4 135.8  9.5 <0.001
24-h diastolic BP (mmHg) 85.2  7.5 82.7  6.1 87.6  9.5 0.013
24-h pulse pressure (mmHg) 46.3  6.2 45.5  6.2 48.2  5.9 0.105
24-h mean BP (mmHg) 100.6  7.4 97.9  5.9 103.5  9.1 0.004
24-h heart rate (beats min1) 75.2  8.1 74.7  8.3 76.2  7.7 0.496
*Value obtained by chi-square test performed between the three subgroups of never, former and current smokers.
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Fig. 1 Carotid-femoral pulse wave velocity (PWV) in normoal-
buminuric and microalbuminuric essential hypertensives. The
P-value in parentheses represents probability after adjustment, by
ancova, for 24-h systolic and diastolic blood pressures and body
mass index.
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mean pressures in the multiple regression model
(b ¼ 0.37; P ¼ 0.007).
Discussion
Microalbuminuria may be considered a marker of
vascular dysfunction, which is not confined to the
renal arterial bed alone, whereas carotid-femoral
PWV is an indicator of the aortic stiffness. Both these
parameters have been identified as independent
predictors of cardiovascular morbidity and mortality
[1–22]. Nevertheless, the relationship between AER
and large artery stiffening has not been fully elucidated.
Recently, in the Losartan Intervention for End-
point reduction (LIFE) study, by using the pulse
pressure/stroke index ratio (PP/SVi), as an approxi-
mate indirect estimate of the overall stiffness of the
systemic arterial tree, Palmieri et al. found a ten-
dency towards greater values of albuminuria in
patients of the third tertile of PP/SVi, when com-
pared with the lower tertiles, even if this difference
was not statistically significant [24].
When more direct measures of aortic stiffness
were employed a close association between AER and
reduced aortic compliance was observed. For exam-
ple, several years ago Takegoshi found a significant
association between PWV and AER in 40 diabetic
patients [25]. This finding was recently confirmed in
37 subjects with type 2 diabetes [26]. An even
stronger correlation between these two variables
was observed in a group of nonsmoking patients
with essential hypertension [27]. Consistent with
these reports Tsioufis et al. showed abnormal aortic
root distensibility, assessed by transthoracic echo-
cardiography, in microalbuminuric hypertensives
when compared with normoalbuminuric ones [28].
The same authors documented more recently that
an earlier systolic augmentation in the carotid
arterial pressure contour (i.e. an increased augmen-
tation index reflecting a more impaired arterial
elasticity) was significantly and independently asso-
ciated with greater values of AER in untreated
patients with essential hypertension [29].
Our results seem to be in keeping with these
previous data. Indeed, the main finding of the
present study was the identification of a strong
correlation between carotid-femoral PWV and AER
in a sample of newly diagnosed and untreated
nondiabetic hypertensive subjects. Moreover, the
Table 2 Univariate correlations
between albumin excretion rate
(AER), aortic pulse wave velocity
(PWV) and some demographic and
clinical variables in the whole
study population (n ¼ 70). Bold
numbers represent correlations of
statistical significance. Italic num-
bers indicate correlations of bor-
derline statistical significance.
PWV P-value (LOG) AER P-value
Age 0.48 0.00003 0.05 NS
Body mass index 0.32 0.007 0.27 0.02
Glycaemia 0.23 0.055 0.15 NS
Creatinine clearance 0.14 NS 0.30 0.01
Clinic systolic blood pressure 0.52 0.000004 0.31 0.009
Clinic diastolic blood pressure 0.34 0.004 0.37 0.002
Clinic pulse pressure 0.42 0.0003 0.13 NS
Clinic mean blood pressure 0.47 0.00004 0.37 0.002
24-h systolic blood pressure 0.49 0.00002 0.42 0.0003
24-h diastolic blood pressure 0.31 0.009 0.32 0.007
24-h pulse pressure 0.39 0.0008 0.25 0.037
24-h mean blood pressure 0.40 0.0006 0.37 0.002
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Fig. 2 Scatter-plot showing the relation between carotid-femoral
pulse wave velocity and albumin excretion rate (transformed as a
logarithm for its skewed distribution). Dashed hyperbolic lines
represent the 95% confidence bands around the regression line.
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results of multiple regression analysis showed that
this association was independent of some potential
confounders, known determinants of aortic compli-
ance and/or microalbuminuria, such as BP, age,
gender, smoking habits, BMI and glycaemia.
Moreover, splitting the study population in micro-
albuminuric and normoalbuminuric subjects we
found greater values of aortic PWV in patients with
microalbumuria. Similar conclusions were obtained
when the subjects were divided into two subgroups
on the basis of the median value of the distribution
of AER (15.3 lg min1), that is below the currently
considered threshold for the definition of microalbu-
minuria (20 lg min1). Indeed, recent evidence
from cross-sectional [4] and prospective studies
[14, 16–18] supports the adoption of a lower AER
cut-off point for the detection of enhanced cardio-
vascular risk in individuals with arterial hyperten-
sion. This probably reflects the fact that
microalbuminuria was originally defined on the
basis of increased risk for developing diabetic
nephropathy. It is now clear that its significance
extends beyond nephropathy and it likely mirrors a
more widespread vascular injury [33].
The present study was designed to determine
whether or not an association between albuminuria
and aortic PWV exists, but it does not provide
information on the mechanisms of this relationship.
Since both microalbuminuria and aortic PWV have
been associated with endothelial dysfunction and
subclinical atherosclerosis, these latter may be the
pathophysiological links between AER and impaired
aortic compliance. Indeed, there is some evidence
suggesting that leakage of albumin through the
glomerular membrane is a reflection of a systemic
transvascular macromolecular leakage in atherogen-
esis, where permeability changes occur since the
earliest stage as a consequence of damaged vascular
endothelium, a structure intimately involved in
vascular permeability as well as haemostasis, fibrin-
olysis and vasomotion [34–35]. This hypothesis is
strengthened by the correlations between AER and
circulating endothelium-derived factors secreted in
greater amounts by injured endothelium, as observed
by our group [36] and other investigators [37].
Moreover, previous findings of an association be-
tween greater values of AER and increased carotid
intima-media thickness [5–6] and between the level of
microalbuminuria and the severity of coronary artery
disease [9], further corroborate the view according to
which microalbuminuria may be considered as a
marker of preclinical or established atherosclerosis.
On the other hand, arterial stiffness may be partly
under the functional control of some substances
released from the endothelium, above all endog-
enous nitric oxide [38, 39], as well as being
structurally determined. Moreover, several studies
have highlighted the associations between aortic
PWV, and most cardiovascular risk factors, and
established atherosclerosis [19, 40, 41].
Since both aortic distensibility and microalbu-
minuria have been related with cardiovascular
prognosis, the positive and independent correlation
between PWV and AER that we observed may
account, at least in part, for the respective influence
on cardiovascular diseases. Only future longitudinal
prospective studies, evaluating both aortic PWV and
microalbuminuria, will clarify the independent con-
tribution of each of parameter on cardiovascular
morbidity and mortality.
It is well-known that there is a considerable
intrapersonal variation of urinary albumin excretion
[1]. Therefore, the measurement of only two AER
may be a limitation of our study. However, because
of regression dilution, this may have caused an
underestimation of the existing positive relationship
between urinary albumin excretion and PWV. This
suggests that the true association between AER and
PWV is likely to be even stronger than observed in
the present study. Moreover, in several papers [10,
16–18], in which a relationship between AER and
cardiovascular damage and prognosis was found,
only one or two measurements were performed.
In conclusion, our study, showing a close and
independent relationship between AER and carotid-
femoral PWV, seems to confirm the concept accord-
ing to which microalbuminuria represents the early
renal manifestation of a generalized vascular dys-
function, and therefore it is an integrated marker of
cardiovascular risk.
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